Search results
Results From The WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. [ 25 ] [ 26 ] The drug was provided by the company in response to a " compassionate use " (temporary authorization for use) request from the president's physicians.
Baxter International was founded in 1931 by Donald Baxter, a Los Angeles -based medical doctor, as a manufacturer and distributor of intravenous therapy solutions. [4] Seeing a need for products closer to the Midwest, the company opened a manufacturing plant in Glenview, Illinois, in 1933. [4] Baxter's interest was bought out in 1935 by Ralph ...
August 20, 2024 at 7:17 PM. (Reuters) -The U.S. Food and Drug Administration has declined to approve Regeneron's therapy for a common form of blood cancer, the company said on Tuesday. Regeneron ...
Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. [2] The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 [3] making Schleifer a billionaire. [2] In 2014 Eylea grossed $1.735 billion. [4]
Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo
Formula. C6458H9950N1728O2020S46. Molar mass. 145 593.47 g·mol −1. Odronextamab, sold under the brand name Ordspono, is a CD20 x CD3 bispecific monoclonal antibody that is used for the treatment of follicular lymphoma or diffuse large B-cell lymphoma. [1][2] It was developed by Regeneron Pharmaceuticals.
The company was founded in 1987 by Michael Wall. [3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. [4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington ...